Objective: This is the initial 12-month outcomes of patients treated for chronic symptomatic aortic dissection by the Streamliner Multilayer Flow Modulator (SMFM; Cardiatis, Isnes, Belgium). Primary end points were freedom from rupture and aortic-related death and reduction in false lumen index. Secondary end points were patency of great vessels and visceral branches and freedom from stroke, paraplegia, and renal failure.
Early-Access Upper Extremity Grafts Offer No Benefit Over Standard Grafts in Hemodialysis Access
John DelBianco, BA, Samuel Steerman, MD, David Dexter, MD, Sadaf Ahanchi, MD, Gordon Stokes, MD, Sarah Ongstad, MD, Obie Powell, MD, Niraj Parikh, MBBS, Jean Panneton MD. Eastern Virginia Medical School, Norfolk, VA Objective: The objective of this study was to compare the patency, tunneled dialysis catheter days, and complications of early-access arteriovenous grafts (EAGs) and standard arteriovenous grafts (AVGs).
Methods: A retrospective chart review was conducted of patients who received an expanded polytetrafluoroethylene AVG from January 2011 to March 2012. HeRO grafts (Merit Medical Systems, South Jordan, Utah) and lower extremity AVGs were excluded. The primary end points were primary, primary assisted, and secondary patency and the number of days from index operation until tunneled dialysis catheter removal, termed catheter days. The secondary end point was the number of access-related complications, including infection and steal.
Results: There were 122 expanded polytetrafluoroethylene AVGs placed in 115 patients; 78 were standard AVGs and 44 were EAGs. The standard AVG group included 15 Propaten and 10 Gore Hybrid grafts (W. L. Gore & Associates, Flagstaff, Ariz); 22 Advanta grafts (Atrium Medical, Hudson, NH); and 4 Impra, 21 Venaflo, and 6 Carboflo grafts (C.R. Bard, Murray Hill, NJ). The EAG group included 3 Vectra (C.R. Bard), 18 Flixene (Atrium Medical), and 23 Acuseal (W. L. Gore) grafts. The mean age was 66 years, and 41% were male. The age, gender, race, body mass index, and comorbidities were similar between both groups. Mean follow-up was 16 months (15 in standard group vs 18 in EAG group; P ¼ .368). The standard AVG was the first-ever arteriovenous hemodialysis access for 32% of patients compared with 30% with the EAG (P ¼ .839). By Kaplan-Meier analysis, EAGs and standard grafts did not differ in primary (3% for standard vs 2% for EAG; P ¼ .096), primary assisted (7% for standard vs 22% for EAG; P ¼ .203), or secondary patency (28% for standard vs 54% for EAG; P ¼ .366) at 12 months. The number of catheter days was not significantly different between the two groups (61 days for standard vs 44 days for EAG; P ¼ .065). We found the useful life of the grafts to be similar (11.6 months for standard grafts vs 8.6 months for EAG; P ¼ .450). There was no significant difference in the number of reinterventions (2.7 for standard vs 2.4 for EAG; P ¼ .656), incidence of thrombosis (1.4 for standard vs 1.1 for EAG; P ¼ .409), infection (0.15 for standard vs 0.14 for EAG; P ¼ .814), or steal (0.35 for standard vs 0.37 for EAG; P ¼ .792) over the life of the grafts. The groups were similar in both 30-day (P ¼ .545) and overall all-cause mortality (P ¼ .395).
Conclusions: Early-access grafts in our practice were found to have no benefit over standard grafts. The two types of grafts did not differ significantly in primary patency, primary assisted patency, secondary patency, catheter days, number of reinterventions required, or access-related complications. Methods: A retrospective chart review from January 2013 to April 2016 of patients at our institution who underwent placement and modification of the HeRO dialysis system with Acuseal graft was performed. Patient demographics, access history, clinical background, perioperative parameters, complications, and outcomes were analyzed. The majority of the data were described by counts, ranges, and means when relevant. Primary and secondary patency rates as well as hours to successful cannulation were analyzed.
Results: HeRO graft with modification of the arterial component using Acuseal graft was successfully placed during 3 years in 10 patients who were catheter dependent. Average follow-up after successful implantation has been 15.6 months. The primary reason for placement of all HeRO grafts was central venous occlusion and need for hemodialysis arteriovenous access. The mean time to cannulation of the graft was 33.7 hours with 100% success. Postoperative complications included two thromboses and one hematoma. One thrombosis was in the immediate postoperative period that required repositioning of the graft and thrombectomy. At a mean follow-up of 6 months, the primary patency rate was 70% and the secondary patency rate was 90%. One patient at 1.7 months required excision of the HeRO dialysis system because of a primary infection of the graft.
Conclusions: Central venous occlusions and exhausted arteriovenous access are common complications in the chronic hemodialysis population. HeRO graft placement is able to provide a means of access in these patients who otherwise would be left catheter dependent. Our institution's method of using Acuseal graft for immediate cannulation allows an accelerated use of this system, reducing catheter dependence time. With few postoperative complications and comparable patency rates, our modification appears to be both safe and efficacious in enabling early cannulation.
